Home Bull & Bear

Bull & Bear

Bull and Bear

Verdict: Watchlist — the franchise is intact and ~$9B of pre-loaded premium is real, but the equity is paying 37.7x FY26E earnings to underwrite a Medicaid MCR recovery the company itself has refused to commit to. The decisive tension is whether FY2025's blow-up was a sector-wide cyclical reset (Bull) or a structural EPS rebase (Bear). The math that settles it is knife-edge: every 100bps move in Medicaid MCR is worth ~$5 of EPS, and FY2026 is guided 4 percentage points above the long-term target with the rate-vs-trend gap already six quarters old [1][2]. The fact that would change the conclusion is one or two clean quarters of Medicaid MCR converging toward 90% with neutral-to-favorable prior-year development — neither side can claim victory before that print arrives.

Bull Case
No Results

Bull's price target is $280 on 16x FY2027 adjusted EPS of ~$11, anchoring on the embedded-earnings bridge ($5 FY26 floor + $1 MAPD exit + $1.50 Florida Kids run-rate + $2.50 partial Medicaid rate catch-up). Timeline is 18-24 months, with the May 8, 2026 Investor Day expected to quantify the FY2027 baseline and the FY2026 Q3/Q4 prints carrying the rate-cycle signal. The disconfirming signal Bull names is a FY26 Q3 print showing Medicaid MCR materially above the 92.9% guide (94%+), or a loss in either the Texas STAR/CHIP or Washington Apple Health 2028 procurement — either would force a structural reset of the rate-cycle and procurement-engine pillars of the case.

Bear Case
No Results

Bear's downside target is $135 (–31%) using two cross-checks that converge on the same area: (a) 17x peer-stress multiple on FY27 consensus EPS of $8.07 = $137, and (b) 27x on a still-soft $5 FY26 EPS = $135. Timeline is 12-18 months — the Jan 2026 retroactive rate trues, the Jan 2027 cycle, and the May 2026 Investor Day are the verdict windows. The primary trigger is a FY26 print at or above the company's own 92.9% Medicaid MCR guide, or a fourth guidance cut. The cover signal would be two consecutive quarters of Medicaid MCR printing below 90% with neutral-to-favorable PYD in Medicaid and the Marketplace risk-adjustment payable stabilizing rather than building. The bear's three discrete claims that anchor the case — three sequential guidance cuts in 2025 [1], MCR "temporary" framing in the 10-K [2], and the litigation footnote with the class window [7] — are drawn from the primary record verbatim.

The Real Debate

The decisive disagreement is not over the facts of FY2025 — both sides agree on the numbers — but over what those numbers say about FY2027. The crux is the Medicaid MCR knife-edge: the 10-K's own sensitivity table shows a single point of MCR moves FY25 EPS from $8.92 to roughly $2.72 [6], and management characterizes the rate-vs-trend imbalance as "temporary" but has not committed to when it closes [2]. Below the table, the forensic anchor for Tension 3 is also from the 10-K: prior-year development collapsed to $98M [4] while operating cash flow swung to –$535M [5], and the early FY26 read on the most-watched ramp (HIDE/FIDE) came in ahead of plan per the Q1 FY2026 call [3].
No Results

Verdict

Verdict: Watchlist. The bear carries more weight today because the decisive variable — Medicaid MCR — is knife-edge: the 10-K's own sensitivity disclosure shows one point of MCR equals roughly $6.20 of FY25 EPS, and the FY26 Medicaid MCR is guided 4 points above the long-term target with the rate-vs-trend gap already six quarters old [6]. At 37.7x FY26E earnings, the equity is paying for a snap-back to "normalized" $14-20 EPS that management itself has refused to commit to, and the forensic record (prior-year development collapsed to $98M [4], operating cash flow swung to –$535M [5], covenant cut from 3.00x to 1.75x, CEO insider sale at $320 six weeks pre-cut) gives that recovery thin margin of safety. The bull could still be right: the franchise is genuinely intact (zero impairment vs Centene's $6.7B, RBC ~305%, all 21 state licenses), the ~$9B 2025-vintage premium award book is contractually pre-loaded, the HIDE/FIDE ramp came in ahead of plan in Q1 FY2026 [3], and two of three FY27 EPS-bridge legs are mechanical. The durable thesis breaker is whether Medicaid MCR converges toward the 88-89% target — the near-term evidence marker is the FY26 Q3 print (October 2026), where a Medicaid MCR sub-90% with neutral PYD would shift this to Lean Long and a 92%+ print with continued unfavorable PYD would shift it to Avoid. Until then, neither side has earned the conviction the multiple demands.

References

  1. Molina Healthcare, Inc. — Q3 FY2025 Earnings Call Transcript, CEO guidance walk and 2026 setup — p.2
  2. Molina Healthcare, Inc. — FY2025 Annual Report (Form 10-K), Item 7 MD&A Medicaid Segment "rate and trend imbalance… temporary" — p.82
  3. Molina Healthcare, Inc. — Q1 FY2026 Earnings Call Transcript, CEO on HIDE/FIDE conversion performance — p.8
  4. Molina Healthcare, Inc. — FY2025 Annual Report (Form 10-K), Note 10 Medical Claims and Benefits Payable rollforward FY2025 — p.129
  5. Molina Healthcare, Inc. — FY2025 Annual Report (Form 10-K), MD&A Operating Activities — p.88
  6. Molina Healthcare, Inc. — FY2025 Annual Report (Form 10-K), Item 1A Risk Factors — MCR sensitivity (91.7% to 92.7% would cut EPS from $8.92 to $2.72) — p.41
  7. Molina Healthcare, Inc. — FY2025 Annual Report (Form 10-K), Note 15 Commitments and Contingencies — Legal Proceedings (Hindlemann and Taylor) — p.139